Scholarlink

<p>Castration-resistant prostate cancer (CRPC) constitutes an advanced stage of prostate cancer (PCa) that emerges following conventional androgen deprivation therapy (ADT). Docetaxel (DTX), a standard chemotherapeutic agent, is integral to the therapeutic regimen for CRPC. However, the development of resistance to DTX has significantly impeded its clinical efficacy. Histone lactylation and elevated lactate production are emerging as critical factors in cancer biology, yet their roles in CRPC and DTX resistance remain poorly understood. This study investigated the relationship between histone lactylation, lactate production, and DTX resistance in CRPC. Clinical analysis revealed significantly increased pan-lactylated protein (Pan Kla) expression in CRPC tissues compared to PCa, accompanied by elevated lactate production and lactate dehydrogenase (LDH) activity. Higher Pan Kla expression was linked to poor prognosis in CRPC. DTX-resistant CRPC (CRPC-R) samples exhibited significantly elevated Pan Kla and histone lactylation modifications, especially at H3K18la and H4K12la sites. Inhibition of lactate production using 2-deoxyglucose (2-DG) and oxamate reduced DTX resistance, suppressed cell migration, induced G0/G1 phase arrest, and promoted autophagy. Moreover, CNN1 was identified as a potential downstream target of histone lactylation modifications in CRPC. Elevated CNN1 expression correlated with increased lactylation and DTX resistance, whereas its inhibition reversed the effects of lactate inhibition on cell cycle progression and autophagy. In vivo, CNN1 overexpression counteracted the tumor-suppressive effects of lactate inhibition, restoring tumor growth and autophagy levels. These findings suggested that histone lactylation and lactate metabolism, mediated by CNN1, play a crucial role in DTX resistance and tumor progression in CRPC, offering potential therapeutic targets for overcoming chemoresistance in CRPC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Histone lactylation modification promotes docetaxel resistance and tumor progression through CNN1-Mediated autophagy and cell cycle arrest in Castration-resistant prostate cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月13日

查看全文
  • Ruijie Mao,
  • Xu Chen,
  • Xing Fu,
  • Dingyuan Yang,
  • Wenqiang Chen,
  • Jun Li

摘要

Castration-resistant prostate cancer (CRPC) constitutes an advanced stage of prostate cancer (PCa) that emerges following conventional androgen deprivation therapy (ADT). Docetaxel (DTX), a standard chemotherapeutic agent, is integral to the therapeutic regimen for CRPC. However, the development of resistance to DTX has significantly impeded its clinical efficacy. Histone lactylation and elevated lactate production are emerging as critical factors in cancer biology, yet their roles in CRPC and DTX resistance remain poorly understood. This study investigated the relationship between histone lactylation, lactate production, and DTX resistance in CRPC. Clinical analysis revealed significantly increased pan-lactylated protein (Pan Kla) expression in CRPC tissues compared to PCa, accompanied by elevated lactate production and lactate dehydrogenase (LDH) activity. Higher Pan Kla expression was linked to poor prognosis in CRPC. DTX-resistant CRPC (CRPC-R) samples exhibited significantly elevated Pan Kla and histone lactylation modifications, especially at H3K18la and H4K12la sites. Inhibition of lactate production using 2-deoxyglucose (2-DG) and oxamate reduced DTX resistance, suppressed cell migration, induced G0/G1 phase arrest, and promoted autophagy. Moreover, CNN1 was identified as a potential downstream target of histone lactylation modifications in CRPC. Elevated CNN1 expression correlated with increased lactylation and DTX resistance, whereas its inhibition reversed the effects of lactate inhibition on cell cycle progression and autophagy. In vivo, CNN1 overexpression counteracted the tumor-suppressive effects of lactate inhibition, restoring tumor growth and autophagy levels. These findings suggested that histone lactylation and lactate metabolism, mediated by CNN1, play a crucial role in DTX resistance and tumor progression in CRPC, offering potential therapeutic targets for overcoming chemoresistance in CRPC.